712
Participants
Start Date
January 31, 2019
Primary Completion Date
January 31, 2021
Study Completion Date
February 28, 2021
Alirocumab Injectable Product
Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
Saline Solution
The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
Eduard Ilgiyaev, Rishon LeZiyyon
Collaborators (1)
Assaf-Harofeh Medical Center
OTHER_GOV
Sanofi
INDUSTRY
Wolfson Medical Center
OTHER_GOV